In March 2024, CRISPR Therapeutics developed a new gene editing platform with more precision and efficiency, which was announced. This next-gen gene-editing platform is likely to change how people with genetic disorders or rare diseases are treated.
In February 2024, Moderna AI launched an AI-enabled mRNA research framework aimed towards rapid advancement of vaccines and therapeutics. This technology improves the stability and efficacy of mRNA by optimizing its sequence, which can be used in future cancer and infectious disease treatment.
In January 2024, Biogen partnered with Google DeepMind with a goal to inject AI and machine learning into research focused on neurodegenerative diseases to speed up drug development for Alzheimer’s and Parkinson’s. The goal of this collaboration is to improve biomarker discovery and make clinical studies more efficient.
December 2023 – Ginkgo Bioworks automated bioengineering platform for large-scale microbial fermentation, the company's latest addition to its range of tools making biology easier to engineer. It facilitates the eco-friendly manufacturing of bio-based chemicals, pharmaceuticals, and alternative proteins, sustainably produced using biofermentation processes.
Impact on Industry
The biotechnology industry is expected to grow significantly, reaching an estimate of USD 2,330.47 billion by 2032. During the period from 2025 to 2032, expansion is projected to surge at a 12.3 percent CAGR pace due to a multitude of pivotal growth drivers.
AI-powered research is fundamentally changing the world of biotechnology by streamlining drug development, advancing precision medicine, and improving disease diagnostics. With the adoption of machine learning models along with big data analytics, it is now possible to analyze expansive genomic information, forecast treatment outcomes, and pinpoint promising therapeutic compounds at unprecedented speed.
At the same time, new developments in bioengineering and fermentation are changing biomanufacturing by making possible the production of environmentally benign chemicals, pharmaceuticals, and materials. There is also a shift from bio-based solutions integration to the food and nutrition sector, where alternative proteins and cultured meat products are poised as more sustainable food options.